All In Biotech

Drug Trial Radar · NCT07920809

A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, Phase Ib study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HSK60002 tablets in approximately 60 participants with moderate-to-severe atopic dermatitis (AD). Participants are randomized within one of three dose groups in a 4:1 ratio to HSK60002 or matching placebo. Treatment is given orally for up to 16 weeks (Stage 1: Weeks 1-4; Stage 2: Weeks 5-16), followed by a safety follow-up visit approximately 2 weeks after the last dose.

Conditions

  • Dermatitis Atopic

Interventions

  • HSK60002 tabletsDrug

    HSK60002 tablets, oral administration.

  • HSK60002 PlaceboDrug

    Placebo tablets, oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)Time frame: From first dose (Day 1) through Week 16 (end of treatment) and the safety follow-up visit approximately 2 weeks after the last dose.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.